The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune checkpoint blockade in locally advanced rectal cancer with deficient mismatch repair (dMMR): Retrospective multicenter experience.
 
Oluwadunni Emiloju
Stock and Other Ownership Interests - Telix Pharmaceuticals
 
Preksha Shah
No Relationships to Disclose
 
Aman Opneja
Consulting or Advisory Role - Pfizer; Taiho Oncology
 
Anupama Gupta
No Relationships to Disclose
 
Meghana Singh
No Relationships to Disclose
 
Anwaar Saeed
Consulting or Advisory Role - Arcus therapeutics; Astellas Pharma; AstraZeneca; Autem Therapeutics; Autem therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer; Regeneron; Replimune; Taiho Pharmaceutical; Xilio therapeutics
Research Funding - Actuate Therapeutics (Inst); Arcus therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Incyte (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Oxford biotherapeutics (Inst); Phanes Therapeutics (Inst); Replimune (Inst)
 
John Strickler
Stock and Other Ownership Interests - Triumvira Immunologics, Inc
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; GE Healthcare; GlaxoSmithKline; Incyte; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Leap Therapeutics; Lilly; Merck; Natera (Inst); Pfizer; Quanta Therapeutics; Regeneron; Roche/Genentech; Sanofi; Seagen; Taiho Oncology; Takeda; Xilio Therapeutics
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); Apollo Therapeutics; AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Lilly (Inst); Novartis; Pfizer; Quanta Therapeutics (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst)
Expert Testimony - Seagen
 
Michael Overman
Consulting or Advisory Role - 3T BioSciences; Agenus; Bristol-Myers Squibb; Eisai; Janssen; Merck; Pfizer; Roche/Genentech; Simcere; Summit Therapeutics
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Frank Sinicrope
Employment - MedVal (I)
Stock and Other Ownership Interests - Lilly
Consulting or Advisory Role - Guardant Health; Roche
Research Funding - Ventana Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - Patent royalty related to immune markers in colon cancer. Patent jointly held between myself and Roche/Ventana Medical Systems. (Inst)